Results 161 to 170 of about 10,985 (213)
Some of the next articles are maybe not open access.
Miltefosine and cutaneous leishmaniasis
Current Opinion in Infectious Diseases, 2012Miltefosine is a new oral treatment against leishmaniasis. The evidence about its use in New and Old World cutaneous leishmaniasis is presented and discussed.Miltefosine is being tested with small clinical trials mainly in endemic cutaneous leishmaniasis regions of South America and Iran.
Paulo R L, Machado, Gerson, Penna
openaire +2 more sources
Effect of miltefosine on erythrocytes
Toxicology in Vitro, 2013Miltefosine, an alkylphosphocholine drug with antiparasite, antibacterial, antifungal and antineoplastic potency, is the only oral drug that can be used to treat visceral and cutaneous leishmaniasis. The effect of miltefosine is at least partially due to triggering of apoptosis.
Carlos, Munoz +4 more
openaire +2 more sources
Miltefosine to treat leishmaniasis
Expert Opinion on Pharmacotherapy, 2005Leishmaniasis exists in both visceral and cutaneous forms, and miltefosine is the first oral agent with demonstrable efficacy against both types of this disease. At a dose of approximately 2.5 mg/kg/day for 28 days, miltefosine is > 90% curative for visceral disease in India and cutaneous disease in Colombia.
openaire +2 more sources
An update on the clinical pharmacology of miltefosine in the treatment of leishmaniasis
International Journal of Antimicrobial Agents, 2022Thomas P C Dorlo
exaly